News & Events

Kirin Holdings to Double Lactococcus Lactis Strain Plasma Production

September 9, 2021 Tokyo, Japan

iMUSE Health Science Factory to boost production capacity to about 28 tons in 2023.

Kirin Holdings Company, Limited (Kirin Holdings) announces that it will expand manufacturing equipment at the iMUSE Health Science Factory (located in Saitama Prefecture, just north of Tokyo) - a manufacturing center for lactic acid bacteria raw material - in order to meet the increasing demand for Kirin's proprietary Lactococcus lactis strain Plasma (L. lactis strain Plasma), the functional ingredient in the popular iMUSE brand of immune maintenance products. The new manufacturing equipment is scheduled to begin operating in 2023, and will double the annual production capacity of L. lactis strain Plasma to approximately 28 tons in 2023.

To read more, visit KirinHoldings.com.


‹ Back to 2021